SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Corcept Therapeutics Incorporated on behalf of investors who purchased or acquired the company's common stock between October 31, 2024, and December 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit alleges that the defendants made misrepresentations regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, which is Corcept's lead product candidate for multiple indications, including treatment for hypercortisolism [5] Group 2: Legal Actions and Options - Investors who purchased Corcept common stock are encouraged to discuss their legal rights and options, with contact information provided for the Investor Relations Manager [3] - Individuals wishing to serve as lead plaintiff must file necessary papers by April 21, 2026, and can still share in any recovery without serving as lead plaintiff [4]